244 related articles for article (PubMed ID: 26049552)
1. Effect of Ranolazine Monotherapy on Glycemic Control in Subjects With Type 2 Diabetes.
Eckel RH; Henry RR; Yue P; Dhalla A; Wong P; Jochelson P; Belardinelli L; Skyler JS
Diabetes Care; 2015 Jul; 38(7):1189-96. PubMed ID: 26049552
[TBL] [Abstract][Full Text] [Related]
2. Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study.
Ji L; Ma J; Li H; Mansfield TA; T'joen CL; Iqbal N; Ptaszynska A; List JF
Clin Ther; 2014 Jan; 36(1):84-100.e9. PubMed ID: 24378206
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.
Moretto TJ; Milton DR; Ridge TD; Macconell LA; Okerson T; Wolka AM; Brodows RG
Clin Ther; 2008 Aug; 30(8):1448-60. PubMed ID: 18803987
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina).
Kosiborod M; Arnold SV; Spertus JA; McGuire DK; Li Y; Yue P; Ben-Yehuda O; Katz A; Jones PG; Olmsted A; Belardinelli L; Chaitman BR
J Am Coll Cardiol; 2013 May; 61(20):2038-45. PubMed ID: 23500237
[TBL] [Abstract][Full Text] [Related]
5. Randomized, Double-Blind Trial of Triple Therapy With Saxagliptin Add-on to Dapagliflozin Plus Metformin in Patients With Type 2 Diabetes.
Matthaei S; Catrinoiu D; Celiński A; Ekholm E; Cook W; Hirshberg B; Chen H; Iqbal N; Hansen L
Diabetes Care; 2015 Nov; 38(11):2018-24. PubMed ID: 26324329
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
Frias JP; Nauck MA; Van J; Kutner ME; Cui X; Benson C; Urva S; Gimeno RE; Milicevic Z; Robins D; Haupt A
Lancet; 2018 Nov; 392(10160):2180-2193. PubMed ID: 30293770
[TBL] [Abstract][Full Text] [Related]
7. Dutogliptin, a selective DPP4 inhibitor, improves glycaemic control in patients with type 2 diabetes: a 12-week, double-blind, randomized, placebo-controlled, multicentre trial.
Pattzi HM; Pitale S; Alpizar M; Bennett C; O'Farrell AM; Li J; Cherrington JM; Guler HP;
Diabetes Obes Metab; 2010 Apr; 12(4):348-55. PubMed ID: 20380656
[TBL] [Abstract][Full Text] [Related]
8. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.
Dahl D; Onishi Y; Norwood P; Huh R; Bray R; Patel H; Rodríguez Á
JAMA; 2022 Feb; 327(6):534-545. PubMed ID: 35133415
[TBL] [Abstract][Full Text] [Related]
9. Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes.
Wainstein J; Katz L; Engel SS; Xu L; Golm GT; Hussain S; O'Neill EA; Kaufman KD; Goldstein BJ
Diabetes Obes Metab; 2012 May; 14(5):409-18. PubMed ID: 22059736
[TBL] [Abstract][Full Text] [Related]
10. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
[TBL] [Abstract][Full Text] [Related]
11. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.
Frías JP; Guja C; Hardy E; Ahmed A; Dong F; Öhman P; Jabbour SA
Lancet Diabetes Endocrinol; 2016 Dec; 4(12):1004-1016. PubMed ID: 27651331
[TBL] [Abstract][Full Text] [Related]
12. Canagliflozin in Conjunction With Sulfonylurea Maintains Glycemic Control and Weight Loss Over 52 Weeks: A Randomized, Controlled Trial in Patients With Type 2 Diabetes Mellitus.
Yale JF; Xie J; Sherman SE; Garceau C
Clin Ther; 2017 Nov; 39(11):2230-2242.e2. PubMed ID: 29103664
[TBL] [Abstract][Full Text] [Related]
13. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial.
Jadzinsky M; Pfützner A; Paz-Pacheco E; Xu Z; Allen E; Chen R;
Diabetes Obes Metab; 2009 Jun; 11(6):611-22. PubMed ID: 19515181
[TBL] [Abstract][Full Text] [Related]
14. Changes in insulin sensitivity and insulin secretion with the sodium glucose cotransporter 2 inhibitor dapagliflozin.
Mudaliar S; Henry RR; Boden G; Smith S; Chalamandaris AG; Duchesne D; Iqbal N; List J
Diabetes Technol Ther; 2014 Mar; 16(3):137-44. PubMed ID: 24237386
[TBL] [Abstract][Full Text] [Related]
15. Results of the glucose-lowering effect of WelChol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes.
Zieve FJ; Kalin MF; Schwartz SL; Jones MR; Bailey WL
Clin Ther; 2007 Jan; 29(1):74-83. PubMed ID: 17379048
[TBL] [Abstract][Full Text] [Related]
16. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone.
Hollander P; Li J; Allen E; Chen R;
J Clin Endocrinol Metab; 2009 Dec; 94(12):4810-9. PubMed ID: 19864452
[TBL] [Abstract][Full Text] [Related]
17. The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control.
Robinson AC; Burke J; Robinson S; Johnston DG; Elkeles RS
Diabetes Care; 1998 May; 21(5):701-5. PubMed ID: 9589227
[TBL] [Abstract][Full Text] [Related]
18. Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus.
Kovacs CS; Seshiah V; Merker L; Christiansen AV; Roux F; Salsali A; Kim G; Stella P; Woerle HJ; Broedl UC;
Clin Ther; 2015 Aug; 37(8):1773-88.e1. PubMed ID: 26138864
[TBL] [Abstract][Full Text] [Related]
19. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes.
Horton ES; Clinkingbeard C; Gatlin M; Foley J; Mallows S; Shen S
Diabetes Care; 2000 Nov; 23(11):1660-5. PubMed ID: 11092289
[TBL] [Abstract][Full Text] [Related]
20. Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial.
Meier JJ; Rosenstock J; Hincelin-Méry A; Roy-Duval C; Delfolie A; Coester HV; Menge BA; Forst T; Kapitza C
Diabetes Care; 2015 Jul; 38(7):1263-73. PubMed ID: 25887358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
